AZpire Award
This award has been made possible with an unrestricted grant from AstraZeneca to support a project that improves patient support, patient well-being, and clinical outcomes during hematological cancer treatment.
The call for applications for the AZpire Award 2027 is now OPEN!
Hematologists and paramedical professionals are invited to submit their project on behalf of their department and apply for the AZpire Award. All information on rules and regulations are available on the homepage, as is the application form.
The jury will select one winning project based on their innovative character, which will be awarded with EUR 20.000.
The award ceremony will take place at the 42nd BHS General Annual Meeting, March 12-13, 2027.
We are looking forward to receiving outstanding projects that can advance the patient support, patient well-being, and
clinical outcomes during haematological cancer treatment.
Sincerely,
Prof. Ann De Becker, President of the BHS
Submit your project
Participation requirements
The application must preferably be written in English** and must consist of :
- Description of the research project including costs and time frame (max. 2 pages) Detailed project form AZpire Award 2027
- Letter of support by a promoter from the department where the research will be performed (max. 1 page)
- Motivational letter (max 1 page)
- List of publications (if applicable)
- CV
** applications in French or Dutch are acceptable, but the abstract/summary must be in English
Who can apply?
The candidate must fulfill all criteria below:
- be a natural person
- be a member of BHS
- may not be an employee of the pharmaceutical industry
The BHS encourages projects that:
- involves a multidisciplinary team: the project must be supervised by a hematologist but the project leader can be one paramedical professional practicing in a hospital setting (ie. nurse, social worker, pharmacist, physiotherapist)
- consults patients or patient organisations
Which projects are eligible?
- The project must focus on improving patient support, well-being and/or clinical outcomes during cancer treatment in patients with hematological malignancies.
- Projects that improve the patient experience, strengthen supportive care, enhance continuity of care, and
contribute to improved clinical outcomes. - Eligible projects may be clinical, organizational, multidisciplinary, digital, or based on real-world data, provided they demonstrate a clear link with hematology care in the hospital or outpatient setting.